Research platform
Research platform of Noxi Lab allows generating original hybrid molecules from endogenous bioregulators, pharmacologically active compounds and nitric oxide donors (NO-donors)
Main News
* Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma * Gurus raises $0.8M for preclinical trials of a drug for correction of cognitive disorders

Portfolio

Innovative drugs

Innovative drugs
Respiratory system
GUR-501 Asthma treatment First in class

GUR-501 has a potential to be first drug with new mode of action. Asthma causes acute bronchospasm. ~5% of population suffer from asthma. Funded: $721,000. Supported by

Stage: Preclinical trials
Innovative drugs
Genito-urinary system
GUR-001 Erectile dysfunction treatment (ED)

Unique drug candidate that is expected to have a sufficient advantage vs MUSE suppository: higher efficiency and no pain effect. Unlike Caverject, injections are not needed. 25% of men aged 40-70  have moderate ED, and 10% of men have severe ED

Stage: Discovery research
Innovative drugs
Cardiovascular system
GUR-201 Critical Limb Ischemia treatment (CLI) Best-in-class

GUR-201 is designed to treat CLI caused by diabetes or peripheral artery disease. CLI leads to severe complications up to amputation. 1%-2% of population suffer CLI

Stage: Discovery research
Innovative drugs
Respiratory system
GUR-502 COPD treatment (Chronic Obstructive Pulmonary Disease)

COPD is a lung disease characterized by progressive and irreversible airway obstruction and frequent coughing. Main causes are tobacco smoking and air pollution. COPD has no cure yet.  3%-10% of population are suffering from COPD

Stage: Discovery research
Innovative drugs
Nervous system
GUR-802 Parkinson’s disease treatment

In PD a person's brain slowly stops producing a neurotransmitter called dopamine. A person gradually loses the ability to regulate their movements. No cure exist for PD. PD begins at 0.5% of the population aged 60. Medication costs $2500 per year

Stage: Discovery research
Innovative drugs
Nervous system
GUR-803 Nicotine replacement therapy Fast Launch

GUR-803 is a gel which polymerised into biofilm when applied on skin and helps people to quit smoking. Unlike patches Nicorette or NicoDerm CQ it easily applied even on hairy skin, invisible, does not need a removal, and it does not pull out hairs

Stage: Discovery research
Innovative drugs
Cardiovascular system
GUR-202 Stroke treatment

This multi-target drug candidate acts in two ways simultaneously: a) it reduces inflammation in damaged area, to prevent its expansion b) it strengthens a resistance to hypoxia in damaged area. In 55-64 years stroke occurs in 2%-3% of people

Stage: Discovery research
Innovative drugs
Musculo-skeletal system
GUR-601 Advanced NSAIDs development (Nonsteroidal anti-inflammatory drugs)

A proposed approach allows making new NSAIDs without adverse effects, with better therapeutic properties for different indications: cancer pain, migraine, toothache, injury, inflammatory diseases...

Stage: Discovery research

Highly Effective cosmetics

Highly Effective cosmetics
Hair growth stimulation
REG-101 Eyelash growth stimulator Fast Launch

An innovative molecular complex, that more effectively stimulates growth of eyelashes. Competitors are Latisse, Careprost and more than 10 brands on the basis of generic pharmaceutical substance called bimatoprost. ~ 6% of women use  means for eyelash growth

Stage: Clinical tests
Highly Effective cosmetics
Anti-aging line
REG-201 Anti-aging skin recovery Fast Launch

This innovative complex allows to restore moisture and elasticity of the skin by restoring the power of the capillary network, which decreases with age

Stage: Safety study
Highly Effective cosmetics
Hair growth stimulation
REG-103 Hair growth stimulator Fast Launch

This innovative molecular complex acts on hair follicles stimulating hair growth on a head by increasing blood supply to follicles

Stage: Clinical tests
Highly Effective cosmetics
Hair growth stimulation
REG-102 Eyebrow growth stimulator Fast Launch

REG-102 is innovative complex, effectively stimulating the growth of eyebrows by increasing blood supply into a hair follicles. Competitors are products containing bimatoprost, which is a generic pharmaceutical substance. ~ 1% of women use means for eyebrow growth

Stage: Clinical tests
Highly Effective cosmetics
After cosmetic surgery
REG-301 Skin recovery after cosmetic surgery Fast Launch

REG-301 is innovative molecular complex, which is expected to allows  recovering damages after cosmetic surgery several times  faster . These damages comprises scars, hematomas, etc..

Stage: Safety study

Innovative drugs

Respiratory system

Discovery research Preclinical trials Clinical trials
P-IP-II
25%

GUR-501 Asthma treatment

75%

GUR-502 COPD treatment (Chronic Obstructive Pulmonary Disease)

Nervous system

Discovery research Preclinical trials Clinical trials
P-IP-II
80%

GUR-801 Correction of cognitive disorders

80%

GUR-802 Parkinson’s disease treatment

35%

GUR-803 Nicotine replacement therapy

Genito-urinary system

Discovery research Preclinical trials Clinical trials
P-IP-II
80%

GUR-001 Erectile dysfunction treatment (ED)

Cardiovascular system

Discovery research Preclinical trials Clinical trials
P-IP-II
50%

GUR-201 Critical Limb Ischemia treatment (CLI)

50%

GUR-202 Stroke treatment

Musculo-skeletal system

Discovery research Preclinical trials Clinical trials
P-IP-II
50%

GUR-601 Advanced NSAIDs development (Nonsteroidal anti-inflammatory drugs)

Highly Effective cosmetics

Hair growth stimulation

Safety study Clinical tests Product registration
50%

REG-101 Eyelash growth stimulator

50%

REG-102 Eyebrow growth stimulator

50%

REG-103 Hair growth stimulator

Anti-aging line

Safety study Clinical tests Product registration
50%

REG-201 Anti-aging skin recovery

After cosmetic surgery

Safety study Clinical tests Product registration
50%

REG-301 Skin recovery after cosmetic surgery